论文部分内容阅读
目的观察紫杉醇联合顺铂方案新辅助放化疗在进展期食管癌临床治疗中的疗效。方法选取三门峡市中心医院院收治的62例进展期食管癌患者作为研究对象,随机分为对照组与观察组,各31例。观察组予以顺铂联合紫杉醇方案新辅助放化疗,对照组予以5-氟尿嘧啶联合顺铂方案新辅助放化疗。统计两组患者临床效果、毒副反应发生情况及1、2年存活率。结果观察组患者临床总有效率高于对照组,两组差异有统计学意义(P<0.05);两组患者均出现脱发、过敏反应、口腔炎、消化道反应、骨髓抑制、指(趾)麻木等毒副反应,但予以对症处理后,均可得到控制,且对治疗无明显影响。对比两组患者毒副反应,差异无统计学意义(P>0.05);观察组患者1、2年存活率高于对照组,两组差异有统计学意义(P<0.05)。结论对进展期食管癌患者采用紫杉醇联合顺铂方案新辅助放化疗治疗,可显著提高患者的临床总有效率、稳定率及远期生存率,且不增加其毒副反应,在临床治疗中具有重要价值。
Objective To observe the efficacy of neoadjuvant chemoradiation with paclitaxel plus cisplatin in the treatment of advanced esophageal cancer. Methods Sixty - two patients with advanced esophageal cancer who were treated in Sanmenxia Central Hospital were selected as study subjects and randomly divided into control group and observation group, with 31 cases in each. The observation group received neoadjuvant chemoradiation with cisplatin and paclitaxel, and the control group received neoadjuvant chemoradiation with 5-fluorouracil plus cisplatin. Statistics of two groups of patients clinical effect, the incidence of side effects and 1, 2-year survival rate. Results The total clinical effective rate in the observation group was higher than that in the control group, with significant difference between the two groups (P <0.05). Both groups had alopecia, anaphylaxis, stomatitis, digestive tract reaction, myelosuppression, Numbness and other toxic side effects, but to be symptomatic treatment, can be controlled, and no significant effect on treatment. There was no significant difference in the side effects between the two groups (P> 0.05). The survival rate of one and two years in the observation group was significantly higher than that in the control group (P <0.05). Conclusion Paclitaxel combined with cisplatin neoadjuvant chemoradiotherapy in patients with advanced esophageal cancer can significantly improve the clinical total effective rate, stability and long-term survival of patients without increasing its toxicity in clinical treatment with Important value.